BACKGROUND: Treatment of latent tuberculosis in patients infected with the human immunodeficiency virus (HIV) is efficacious, but few patients around the world receive such treatment. We evaluated three new regimens for latent tuberculosis that may be more potent and durable than standard isoniazid treatment. METHODS: We randomly assigned South African adults with HIV infection and a positive tuberculin skin test who were not taking antiretroviral therapy to receiverifapentine (900 mg) plus isoniazid (900 mg) weekly for 12 weeks, rifampin (600 mg) plus isoniazid (900 mg) twice weekly for 12 weeks, isoniazid (300 mg) daily for up to 6 years (continuous isoniazid), or isoniazid (300 mg) daily for 6 months (control group). The primary end point was tuberculosis-free survival. RESULTS: The 1148 patients had a median age of 30 years and a median CD4 cell count of 484 per cubic millimeter. Incidence rates of active tuberculosis or death were 3.1 per 100 person-years in the rifapentine-isoniazid group, 2.9 per 100 person-years in the rifampin-isoniazid group, and 2.7 per 100 person-years in the continuous-isoniazid group, as compared with 3.6 per 100 person-years in the control group (P>0.05 for all comparisons). Serious adverse reactions were more common in the continuous-isoniazid group (18.4 per 100 person-years) than in the other treatment groups (8.7 to 15.4 per 100 person-years). Two of 58 isolates of Mycobacterium tuberculosis (3.4%) were found to have multidrug resistance. CONCLUSIONS: On the basis of the expected rates of tuberculosis in this population of HIV-infected adults, all secondary prophylactic regimens were effective. Neither a 3-month course of intermittent rifapentine or rifampin with isoniazid nor continuous isoniazid was superior to 6 months of isoniazid. (Funded by the National Institute of Allergy and Infectious Diseases and others; ClinicalTrials.gov number, NCT00057122.).
RCT Entities:
BACKGROUND: Treatment of latent tuberculosis in patients infected with the human immunodeficiency virus (HIV) is efficacious, but few patients around the world receive such treatment. We evaluated three new regimens for latent tuberculosis that may be more potent and durable than standard isoniazid treatment. METHODS: We randomly assigned South African adults with HIV infection and a positive tuberculin skin test who were not taking antiretroviral therapy to receive rifapentine (900 mg) plus isoniazid (900 mg) weekly for 12 weeks, rifampin (600 mg) plus isoniazid (900 mg) twice weekly for 12 weeks, isoniazid (300 mg) daily for up to 6 years (continuous isoniazid), or isoniazid (300 mg) daily for 6 months (control group). The primary end point was tuberculosis-free survival. RESULTS: The 1148 patients had a median age of 30 years and a median CD4 cell count of 484 per cubic millimeter. Incidence rates of active tuberculosis or death were 3.1 per 100 person-years in the rifapentine-isoniazid group, 2.9 per 100 person-years in the rifampin-isoniazid group, and 2.7 per 100 person-years in the continuous-isoniazid group, as compared with 3.6 per 100 person-years in the control group (P>0.05 for all comparisons). Serious adverse reactions were more common in the continuous-isoniazid group (18.4 per 100 person-years) than in the other treatment groups (8.7 to 15.4 per 100 person-years). Two of 58 isolates of Mycobacterium tuberculosis (3.4%) were found to have multidrug resistance. CONCLUSIONS: On the basis of the expected rates of tuberculosis in this population of HIV-infected adults, all secondary prophylactic regimens were effective. Neither a 3-month course of intermittent rifapentine or rifampin with isoniazid nor continuous isoniazid was superior to 6 months of isoniazid. (Funded by the National Institute of Allergy and Infectious Diseases and others; ClinicalTrials.gov number, NCT00057122.).
Authors: Taraz Samandari; Tefera B Agizew; Samba Nyirenda; Zegabriel Tedla; Thabisa Sibanda; Nong Shang; Barudi Mosimaneotsile; Oaitse I Motsamai; Lorna Bozeman; Margarett K Davis; Elizabeth A Talbot; Themba L Moeti; Howard J Moffat; Peter H Kilmarx; Kenneth G Castro; Charles D Wells Journal: Lancet Date: 2011-04-12 Impact factor: 79.321
Authors: Stephen D Lawn; Katharina Kranzer; David J Edwards; Matthew McNally; Linda-Gail Bekker; Robin Wood Journal: AIDS Date: 2010-06-01 Impact factor: 4.177
Authors: J L Johnson; A Okwera; D L Hom; H Mayanja; C Mutuluuza Kityo; P Nsubuga; J G Nakibali; A M Loughlin; H Yun; P N Mugyenyi; A Vernon; R D Mugerwa; J J Ellner; C C Whalen Journal: AIDS Date: 2001-11-09 Impact factor: 4.177
Authors: Debra Benator; Mondira Bhattacharya; Lorna Bozeman; William Burman; Antonino Cantazaro; Richard Chaisson; Fred Gordin; C Robert Horsburgh; James Horton; Awal Khan; Christopher Lahart; Beverly Metchock; Constance Pachucki; Llewellyn Stanton; Andrew Vernon; M Elsa Villarino; Yong Chen Wang; Marc Weiner; Stephen Weis Journal: Lancet Date: 2002-08-17 Impact factor: 79.321
Authors: Marc Weiner; Naomi Bock; Charles A Peloquin; William J Burman; Awal Khan; Andrew Vernon; Zhen Zhao; Stephen Weis; Timothy R Sterling; Katherine Hayden; Stefan Goldberg Journal: Am J Respir Crit Care Med Date: 2004-02-12 Impact factor: 21.405
Authors: B Mosimaneotsile; E A Talbot; T L Moeti; N M Hone; G Moalosi; H J Moffat; E J Lee; T A Kenyon Journal: Lancet Date: 2003-11-08 Impact factor: 79.321
Authors: Jonathan E Golub; Silvia Cohn; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Betina Durovni; Richard E Chaisson Journal: Clin Infect Dis Date: 2014-11-02 Impact factor: 9.079
Authors: J L Kadota; A Katamba; A Musinguzi; F Welishe; J Nabunje; J L Ssemata; C A Berger; M R Kamya; J Namusobya; F C Semitala; A Cattamanchi; D W Dowdy Journal: Int J Tuberc Lung Dis Date: 2020-07-01 Impact factor: 2.373
Authors: D Shepardson; S M Marks; H Chesson; A Kerrigan; D P Holland; N Scott; X Tian; A S Borisov; N Shang; C M Heilig; T R Sterling; M E Villarino; W R Mac Kenzie Journal: Int J Tuberc Lung Dis Date: 2013-12 Impact factor: 2.373
Authors: Amita Gupta; Jyoti S Mathad; Susan M Abdel-Rahman; Jessica D Albano; Radu Botgros; Vikki Brown; Renee S Browning; Liza Dawson; Kelly E Dooley; Devasena Gnanashanmugam; Beatriz Grinsztejn; Sonia Hernandez-Diaz; Patrick Jean-Philippe; Peter Kim; Anne D Lyerly; Mark Mirochnick; Lynne M Mofenson; Grace Montepiedra; Jeanna Piper; Leyla Sahin; Radojka Savic; Betsy Smith; Hans Spiegel; Soumya Swaminathan; D Heather Watts; Amina White Journal: Clin Infect Dis Date: 2015-12-09 Impact factor: 9.079